Related Experiment Video
Updated: Apr 23, 2026
05:50
Author Spotlight: Understanding the Mechanism of Tuina Manipulation in Rats
Published on: June 30, 2023
3.5K
Lapatinib ameliorates experimental arthritis in rats
Metin Ozgen1, Suleyman Serdar Koca, Ahmet Karatas
1Department of Rheumatology, Faculty of Medicine, 19 Mayis University, Samsun, Turkey.
Inflammation
|October 7, 2014
Summary
Lapatinib, an EGFR inhibitor, reduced inflammation and joint damage in a rat model of arthritis. This suggests epidermal growth factor receptor plays a key role in arthritis pathogenesis.
Area of Science:
- Immunology
- Pharmacology
- Rheumatology
Background:
- Epidermal growth factor receptor (EGFR) and its ligands are expressed by synovial cells.
- Synovial cells play a role in the pathogenesis of arthritis.
Purpose of the Study:
- To investigate the therapeutic potential of lapatinib, an EGFR tyrosine kinase inhibitor, in collagen-induced arthritis (CIA).
Main Methods:
- Rats with CIA were treated with lapatinib (30 mg/kg/day).
- Serum levels of TNF-α, IL-17, and MDA were measured.
- Tissue activities of SOD, catalase, and GPx were determined.
- Expressions of Nrf2 and HO-1 were analyzed.
Main Results:
- Lapatinib treatment significantly reduced serum TNF-α, IL-17, and MDA levels.
- Lapatinib increased antioxidant enzyme activities (SOD, catalase, GPx).
- Lapatinib decreased Nrf2 and HO-1 expressions.
- Lapatinib ameliorated synovial inflammation and cartilage-bone destruction.
Conclusions:
- EGFR signaling is implicated in the pathogenesis of arthritis.
- Lapatinib demonstrates therapeutic potential for treating arthritis.
